1. Home
  2. Labeler Index
  3. Bryant Ranch Prepack
  4. 72162-2137
  5. Product Images: Donepezil Hydrochloride

Product Images Donepezil Hydrochloride

View Photos of Packaging, Labels & Appearance

Product Label Images

The following 15 images provide visual information about the product associated with Donepezil Hydrochloride NDC 72162-2137 by Bryant Ranch Prepack, such as packaging, labeling, and the appearance of the drug itself. This resource could be helpful for medical professionals, pharmacists, and patients seeking to verify medication information and ensure they have the correct product.

Figure 1. Time-course of the Change from Baseline in ADAS-cog Score for Patients Completing 24 Weeks of Treatment. - donepezil fig1

Figure 1. Time-course of the Change from Baseline in ADAS-cog Score for Patients Completing 24 Weeks of Treatment. - donepezil fig1

Figure 10. Cumulative Percentage of Patients Completing 6 Months of Double-blind Treatment with Particular Changes from Baseline in ADCS-ADL-Severe Scores. - donepezil fig10

Figure 10. Cumulative Percentage of Patients Completing 6 Months of Double-blind Treatment with Particular Changes from Baseline in ADCS-ADL-Severe Scores. - donepezil fig10

Figure 11. Time-course of the Change from Baseline in SIB Score for Patients Completing 24 Weeks of Treatment. - donepezil fig11

Figure 11. Time-course of the Change from Baseline in SIB Score for Patients Completing 24 Weeks of Treatment. - donepezil fig11

Figure 12. Cumulative Percentage of Patients Completing 24 Weeks of Double-blind Treatment with Specified Changes from Baseline SIB Scores. - donepezil fig12

Figure 12. Cumulative Percentage of Patients Completing 24 Weeks of Double-blind Treatment with Specified Changes from Baseline SIB Scores. - donepezil fig12

Figure 13. Frequency Distribution of CIBIC-plus Scores at Week 24. - donepezil fig13

Figure 13. Frequency Distribution of CIBIC-plus Scores at Week 24. - donepezil fig13

Figure 2. Cumulative Percentage of Patients Completing 24 Weeks of Double-blind Treatment with Specified Changes from Baseline ADAS-cog Scores. The Percentages of Randomized Patients who Completed the Study were: Placebo 80%, 5 mg/day 85%, and 10 mg/day 68%. - donepezil fig2

Figure 2. Cumulative Percentage of Patients Completing 24 Weeks of Double-blind Treatment with Specified Changes from Baseline ADAS-cog Scores. The Percentages of Randomized Patients who Completed the Study were: Placebo 80%, 5 mg/day 85%, and 10 mg/day 68%. - donepezil fig2

Figure 3. Frequency Distribution of CIBIC-plus Scores at Week 24. - donepezil fig3

Figure 3. Frequency Distribution of CIBIC-plus Scores at Week 24. - donepezil fig3

Figure 4. Time-course of the Change from Baseline in ADAS-cog Score for Patients Completing the 15-week Study. - donepezil fig4

Figure 4. Time-course of the Change from Baseline in ADAS-cog Score for Patients Completing the 15-week Study. - donepezil fig4

Figure 5. Cumulative Percentage of Patients with Specified Changes from Baseline ADAS-cog Scores. The Percentages of Randomized Patients Within Each Treatment Group Who Completed the Study Were: Placebo 93%, 5 mg/day 90%, and 10 mg/day 82%. - donepezil fig5

Figure 5. Cumulative Percentage of Patients with Specified Changes from Baseline ADAS-cog Scores. The Percentages of Randomized Patients Within Each Treatment Group Who Completed the Study Were: Placebo 93%, 5 mg/day 90%, and 10 mg/day 82%. - donepezil fig5

Figure 6. Frequency Distribution of CIBIC-plus Scores at Week 12. - donepezil fig6

Figure 6. Frequency Distribution of CIBIC-plus Scores at Week 12. - donepezil fig6

Percentage of Patients: This text provides data on the percentage of patients. It indicates percentages of 50, 30, 20, and 10, but the context or subject of these percentages is not clear. Donepezil Hydrochioride Study: The text mentions the use of Donepezil Hydrochioride, a medication prescribed at a dosage of 10mg per day. Placebo: The text mentions the use of a placebo in the study. Improved, Change, and Worse: These terms seem to be related to the evaluation or assessment of patients. However, the specific details or criteria for improvement, change, or worsening are not provided. CIBIC-plus Rating: The text briefly mentions CIBIC-plus, which might refer to a rating system used in the study. However, without more information, it is difficult to determine what this rating entails. Overall, the text provides limited information and lacks clarity.*

Figure 7. Time Course of the Change from Baseline in SIB Score for Patients Completing 6 Months of Treatment. - donepezil fig7

Figure 7. Time Course of the Change from Baseline in SIB Score for Patients Completing 6 Months of Treatment. - donepezil fig7

Figure 8. Cumulative Percentage of Patients Completing 6 Months of Double-blind Treatment with Particular Changes from Baseline in SIB Scores. - donepezil fig8

Figure 8. Cumulative Percentage of Patients Completing 6 Months of Double-blind Treatment with Particular Changes from Baseline in SIB Scores. - donepezil fig8

Figure 9. Time Course of the Change from Baseline in ADCS-ADL-Severe Score for Patients Completing 6 Months of Treatment. - donepezil fig9

Figure 9. Time Course of the Change from Baseline in ADCS-ADL-Severe Score for Patients Completing 6 Months of Treatment. - donepezil fig9

Chemical Structure - donepezil str

Chemical Structure - donepezil str

Label - lbl721622137

Label - lbl721622137

This text appears to be the description of a medication called Donepezil Hydrochloride. Each tablet contains 10 mg of the active ingredient Donepezil. The medication is indicated for treating certain neurological conditions and is available in a container with a child-resistant closure. The recommended storage temperature is between 20°C to 25°C (68°F to 77°F), with allowable excursions between 15°C to 30°C (59°F to 86°F). The National Drug Code (NDC) for this medication is 72162-2137-3. It is important to keep this medication and all medications out of the reach of children. The text also mentions the availability of a Medication Guide for patients, which can be accessed through a specific FDA website.*

* The product label images have been analyzed using a combination of traditional computing and machine learning techniques. It should be noted that the descriptions provided may not be entirely accurate as they are experimental in nature. Use the information in this page at your own discretion and risk.